South Bend Medical Foundation - Your Community Laboratory

test directorySearch Results

Click here to search again.

Test Name:
Glomerular Basement Membrane Antibody Panel

• SBMF No:
  44795
• Performance Lab Name:
  ARUP Laboratories
• Test Mnemonic:
  GBM PAN
• ABN:
  Required – Not FDA-Approved
• CPT Code:
  83516; 86255x2
• LOINC Code:
  29994-1; 44446-3; 29995-8
• Ref Lab Test No:
  0051001
• Test Includes:
  Glomerular Basement Membrane IgA Antibody, by IFA
  Glomerular Basement Membrane IgG Antibody, by IFA
  Glomerular Basement Membrane IgG Antibody, by MAFD
• Also Known As:
  Anti-GBM Antibody Panel
  Anti-Glomerular Basement Membrane Antibody Panel
  GBM Antibody Panel
• Spec Type:
  Serum
• Spec Container:
  Gold top (SST) or red top (serum) tube
• Pref Vol:
  Two 1.0 mL aliquots of serum
• Min Vol:
  Two 0.5 mL aliquots of serum
• Fasting:
  No
• Spec Collect:
  Routine venipuncture
• Spec Process:
  Clot 30 minutes
  Promptly centrifuge 15 minutes
  Immediately transfer serum to two (2) separate plastic tubes
• Spec Store Transport:
  Refrigerated
• Spec Stability:
  After separation from cells:
  48 hours room temperature (20-30°C)
  2 weeks refrigerated (2-8°C)
  1 year frozen (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles
• Spec Remarks:
  Separate serum from cells ASAP
• Methodology:
  Indirect Fluorescent Antibody (IFA)
  Multi-Analyte Fluorescent Detection (MAFD)
• Clinical Significance:
  Refer to:
  
• Reference Range:
  

  Glomerular Basement Membrane Antibody, IgA (IFA)
  Negative

  Glomerular Basement Membrane Antibody, IgG (IFA)
  Negative

  Glomerular Basement Membrane Antibody, IgG by Multi-Analyte Fluorescent Detection
  Negative: 19 AU/mL or less
  Equivocal: 20-25 AU/mL
  Positive: 26 AU/mL or greater

  Interpretive Data:
  The anti-GBM IFA methodology has been shown to be less specific than the quantitative tests for circulating antibodies such as the Glomerular Basement Membrane Antibody, IgG by Multi-Analyte Fluorescent Detection. The antibody used in this assay, although directed to human IgG F(ab')2, can bind to light chain sites common to all immunoglobulins causing it to be more sensitive but less specific. The determination of a positive result is based upon a diffuse "linear" staining pattern as viewed through a fluorescent microscope, all positive results should be confirmed by quantitative tests and/or renal biopsy.

  The presence of anti-glomerular basement membrane (GBM) antibodies by multi-analyte fluorescent detection (MAFD) may aid in the diagnosis of Goodpasutre syndrome. False positive results may occur due to reactivity against other chains of type IV collagen. If MAFD is negative but there is strong suspicion for disease, renal biopsy may be indicated. A renal biopsy may also be essential in suspected Goodpasture disease with renal involovement, allowing diagnostic confirmation and assesssment of renal prognosis.

• Additional Test Info:
  This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
• Day Run:
  Mon-Fri
• Time Reported:
  2-6 days
• Test Type:
  IMMUNOLOGY